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SUMMARY
Enhancers control the correct temporal and cell type-specific activation of gene expression in 
higher eukaryotes. Knowing their properties, regulatory activity and targets is crucial to 
understand the regulation of differentiation and homeostasis. We use the FANTOM5 panel of 
samples covering the majority of human tissues and cell types to produce an atlas of active, in vivo 
transcribed enhancers. We show that enhancers share properties with CpG-poor mRNA promoters 
but produce bidirectional, exosome-sensitive, relatively short unspliced RNAs, the generation of 
which is strongly related to enhancer activity. The atlas is used to compare regulatory programs 
between different cells at unprecedented depth, identify disease-associated regulatory single 
nucleotide polymorphisms, and classify cell type-specific and ubiquitous enhancers. We further 
explore the utility of enhancer redundancy, which explains gene expression strength rather than 
expression patterns. The online FANTOM5 enhancer atlas represents a unique resource for studies 
on cell type-specific enhancers and gene regulation.
INTRODUCTION
Precise regulation of gene expression in time and space is required for development, 
differentiation and homeostasis in higher organisms1. Sequence elements within or near core 
promoter regions contribute to regulation2, but promoter-distal regulatory regions like 
enhancers are essential in the control of cell type specificity1. Enhancers were originally 
defined as remote elements that increase transcription independent of their orientation, 
position and distance to a promoter3. They were only recently found to initiate RNA 
polymerase II (RNAPII) transcription, producing so-called eRNAs4. Genomic locations of 
enhancers used by cells can be detected by mapping of chromatin marks and transcription 
factor binding sites from chromatin immunoprecipitation (ChIP) assays and DNase I 
hypersensitive sites (DHSs) (reviewed in ref. 1), but there has been no systematic analysis of 
enhancer usage in the large variety of cell types and tissues present in the human body. 
Using Cap Analysis of Gene Expression5 (CAGE), we show that enhancer activity can be 
detected through the presence of balanced bidirectional capped transcripts, enabling the 
identification of enhancers from small primary cell populations. Based upon the FANTOM5 
CAGE expression atlas encompassing 432 primary cell, 135 tissue and 241 cell line samples 
from human6, we identify 43,011 enhancer candidates and characterize their activity across 
the majority of human cell types and tissues. The resulting catalogue of transcribed 
enhancers enables classification of ubiquitous and cell type-specific enhancers, modeling of 
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physical interactions between multiple enhancers and TSSs, and identification of potential 
disease-associated regulatory single nucleotide polymorphisms (SNPs).
RESULTS
Bidirectional pairs of capped RNAs identify active enhancers
The FANTOM5 project has generated a CAGE-based transcription start site (TSS) atlas 
across a broad panel of primary cells, tissues, and cell lines covering the vast majority of 
human cell types6. Within that dataset, well-studied enhancers often have CAGE peaks 
delineating nucleosome-deficient regions (NDRs) (Supplementary Fig. 1). To determine 
whether this is a general enhancer feature, FANTOM5 CAGE (Supplementary Table 1) was 
superimposed on active (H3K27ac-marked) enhancers defined by HeLa-S3 ENCODE ChIP-
seq data7. CAGE tags showed a bimodal distribution flanking the central P300 peak, with 
divergent transcription from the enhancer (Fig. 1a). Similar patterns were observed in other 
cell lines (Supplementary Fig. 2a). Enhancer-associated reverse and forward strand 
transcription initiation events were, on average, separated by 180 bp and corresponded to 
nucleosome boundaries (Supplementary Figs 3 and 4). As a class, active HeLa-S3 enhancers 
had 231-fold more CAGE tags than polycomb-repressed enhancers, suggesting that 
transcription is a marker for active usage. Indeed, ENCODE-predicted enhancers7 with 
significant reporter activity8 had greater CAGE expression levels than those lacking reporter 
activity (P<4e-22, Mann-Whitney U test). A lenient threshold on enhancer expression 
increased the validation rate of ENCODE enhancers from 27% to 57% (Supplementary Fig. 
5).
While capped RNAs of protein-coding gene promoters were strongly biased towards the 
sense direction, similar levels of capped RNA in both directions were detected at enhancers 
(Fig. 1b, and Supplementary Fig. 2b, c). Thus, bidirectional capped RNAs is a signature 
feature of active enhancers. On this basis, we identified 43,011 enhancer candidates across 
808 human CAGE libraries (see Supplementary Text and Supplementary Figs 6-8). 
Interestingly, the candidates were depleted of CpG islands (CGI) and repeats (with the 
exception of neural stem cells, see ref. 9).
To confirm the activity of newly-identified candidate enhancers, we randomly selected 46 
strong, 41 moderate and 36 low activity enhancers (as defined by CAGE tag frequency) and 
examined their activity using enhancer reporter assays compared to randomly selected 
untranscribed loci with regulatory potential in HeLa-S3 cells: 15 DHSs10, 26 ENCODE-
predicted ‘strong enhancers’7 and 20 enhancers defined as in Figure 1A (Supplementary 
Tables 2 and 3). While 67.4-73.9% of the CAGE-defined enhancers showed significant 
reporter activity, only 20-33.3% of the untranscribed candidate regulatory regions were 
active (Fig. 1c, and Supplementary Fig. 9a). The same trend was observed in HepG2 cells 
(Supplementary Fig. 10a, b). Corresponding promoter-less constructs showed that the 
enhancer transcription read-through is negligible (Supplementary Fig. 9b, c). Large fractions 
of CAGE-defined enhancers overlapped predicted ENCODE ‘strong enhancers’ or ‘TSS’ 
states (25% and 62%, respectively, for HeLa-S3), but there was no substantial difference in 
validation rates between these classes (Supplementary Fig. 10c, d). In summary, active 
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CAGE-defined enhancers were much more likely to be validated in functional assays than 
untranscribed candidate enhancers defined by histone modifications or DHSs.
Enhancer TSSs share regulatory features with mRNA TSSs but produce short, exosome-
sensitive RNAs
RNA-seq data from matching primary cells and tissues showed that ~95% of RNAs 
originating from enhancers were unspliced and typically short (median 346 nt) - a striking 
difference to mRNAs (19% unspliced, median 56 nt) (Fig. 2a, and Supplementary Fig. 11a-
c). Unlike TSSs of mRNAs, which are enriched for predicted 5’ splice sites but depleted of 
downstream polyadenylation (pA) signals11,12, enhancers showed no evidence of associated 
downstream RNA processing motifs, and thus resemble antisense PROMoter uPstream 
Transcripts (PROMPTs)11 (Fig. 2b, and Supplementary Fig. 11d). Most CAGE-defined 
enhancers gave rise to nuclear (>80%) and non-polyadenylated (~90%) RNAs13 
(Supplementary Fig. 11e). Based on RNA-seq, few enhancer RNAs overlap exons of known 
protein-coding genes or lincRNAs (9 and 1 out of 4208 enhancers detected, respectively), 
suggesting that they are not a substantial source of alternative promoters for known genes (as 
in ref. 14).
TSS-associated, uncapped small RNAs (TSSa-RNAs), attributed to RNAPII protection and 
found immediately downstream of mRNA TSSs15,16, were detectable in the same positions 
downstream of enhancer TSSs (Supplementary Fig. 12), indicating that RNAPII initiation at 
enhancer and mRNA TSSs is similar. Indeed, CAGE-defined enhancer TSSs resembled the 
proximal position-specific sequence patterns of non-CGI RefSeq TSSs (Fig. 2c, and 
Supplementary Fig. 13a). Furthermore, de novo motif analysis revealed sequence signatures 
in CAGE-defined enhancers closely resembling non-CGI promoters (Fig. 2d, and 
Supplementary Fig. 13b).
Because of the similarity with PROMPTs, we reasoned that capped enhancer RNAs might 
be rapidly degraded by the exosome. Indeed, siRNA-mediated depletion of the hMTR4 
(SKIV2L2) co-factor of the exosome complex resulted in a median 3.14-fold increase of 
capped enhancer-RNA abundance (Fig. 2e, and Supplementary Fig. 14a, b), but only a 
negligible increase at mRNA TSSs. This increasing trend is similar to that of PROMPT 
regions upstream of TSSs, although the increase of enhancer RNAs was significantly higher 
(P<4.6e-67, Mann-Whitney U test, Fig. 2e, and Supplementary Fig. 14b, c). Thus, the 
bidirectional transcriptional activity observed at enhancers is also present at promoters, as 
suggested previously17, but in promoters only the antisense RNA is degraded. Furthermore, 
the CAGE expression of enhancers in control and hMTR4-depleted cells was proportional 
(Supplementary Fig. 14d), suggesting that virtually all identified enhancers produce 
exosome-sensitive RNAs. The number of detectable bidirectional CAGE peaks increased 
1.7-fold upon hMTR4 depletion and novel enhancer candidates had on average similar, but 
weaker, chromatin modification signals compared to control HeLa cells (Supplementary Fig. 
14e).
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CAGE expression identifies cell-specific enhancer usage
To test whether CAGE expression can identify cell type-specific enhancer usage in vivo, 
ChIP-seq (H3K27ac and H3K4me1), DNA methylation and triplicate CAGE analyses were 
performed in five primary blood cell types, and compared to published DHS data 
(www.roadmapepigenomics.org, Supplementary Table 4). CAGE-defined enhancers were 
strongly supported by proximal H3K4me1/H3K27ac peaks (71%) and DHSs (87%) from the 
same cell type. Conversely, H3K4me1 and H3K27ac supported only 24% of DHSs distal to 
promoters and exons and only 4% of DHSs overlapped CAGE-defined enhancers 
(Supplementary Fig. 15), suggesting that a minority of promoter-distal DHSs identify 
enhancers. From the opposite perspective, only 11% of H3K4me1/H3K27ac loci overlapped 
CAGE-defined enhancers and untranscribed loci showed weaker ChIP-seq signals than 
transcribed ones (Supplementary Fig. 16). Moreover, there was a clear correlation between 
CAGE, DNase I hypersensitivity, H3K4me1 and H3K27ac for CAGE-defined enhancers 
expressed in blood cells (Fig. 3a). Accordingly, cell type-specific enhancer expression 
corresponds to cell type-specific histone modifications (Fig. 3b). The majority of selected 
cell type-specific enhancers could be validated in corresponding cell lines and were 
associated with cell type-specific DNA demethylation (Supplementary Text, Supplementary 
Fig. 17, and Supplementary Tables 5-8, see also ref. 18). Thus, bidirectional CAGE pairs are 
robust predictors for cell type-specific enhancer activity.
An atlas of transcribed enhancers over human cells and tissues
The FANTOM5 CAGE library collection6 enables the dissection of enhancer usage across 
cell types and tissues comprehensively sampled across the human body. Clustering based 
upon enhancer expression clearly grouped functionally-related samples together (Fig. 3c, 
and Supplementary Figs 18 and 19). While fetal and adult tissue often grouped together, two 
large fetal-specific clusters were identified: one brain-specific (pink) and one with diverse 
tissues (green). The fetal-brain cluster is associated with enhancers that are located close to 
known neural developmental genes, including NEUROG2, SCRT2, POU3F2 and MEF2C 
(Supplementary Fig. 18b), for which gene expression patterns correlate with enhancer RNA 
abundance across libraries, suggesting regulatory interaction (see below). The results 
corroborate the functional relevance of these enhancers for tissue-specific gene expression 
and suggest that they are an important part of the regulatory programs of cellular 
differentiation and organogenesis.
To confirm that candidate enhancers can drive tissue-specific gene expression in vivo, five 
evolutionarily conserved CAGE-defined human enhancers (including the POU3F2 and 
MEF2C-proximal enhancers identified above) were tested via Tol2-mediated transgenesis in 
zebrafish embryos. We observed tissue-specific enhancer activity with 3 of 5 fragments, 
which corresponded to the human enhancer tissue expression (Fig. 4). None of three control 
fragments without CAGE signal activated the gata2 promoter (Supplementary Table 9). 
While the sample size is not high enough to reliably estimate the validation rates in 
zebrafish, the correlation between the enhancer usage profiles in zebrafish to those defined 
in human by CAGE is notable.
Andersson et al. Page 5













We grouped the primary cell and tissue samples into larger, mutually exclusive cell type and 
organ/tissue groups (facets), respectively, with similar function or morphology 
(Supplementary Tables 10 and 11). Figure 5 summarizes how many enhancers were detected 
in each facet and the degree of facet-specific CAGE expression (see also Supplementary Fig. 
21). From the data we can draw several conclusions:
First, the majority of detected enhancers within any facet are not restricted to that facet. 
Exceptions, where facets use a higher fraction of specific enhancers include immune cells, 
neurons, neural stem cells and hepatocytes amongst the cell type facets, and brain, blood, 
liver and testis amongst the organ/tissue facets.
Second, despite their apparent promiscuity, enhancers are more generally detected in a much 
smaller subset of samples than mRNA transcripts (Supplementary Figs 21, and 22a, b), 
consistent with cell line studies7 and the higher specificity of non-coding RNAs (ncRNAs) 
in general13. Facets in which we detect many enhancers typically also have a higher fraction 
of facet-specific enhancers (Supplementary Fig. 22c, d). Third, the number of detected 
expressed enhancers and mRNA transcripts is correlated (Supplementary Fig. 21b), but the 
number of detected expressed gene transcripts (>1TPM) is 19-34 fold larger than the number 
of detected enhancers with the cutoffs used. Noteworthy exceptions include blood and 
immune cells, testis, thymus, and spleen, which have high enhancer/gene ratios. Conversely, 
smooth and skeletal muscle and skin, bone and epithelia-related cells have low ratios. 
Differential exosome activity between cell types might affect these results, but there was no 
correlation between hMTR4 mRNA expression and the number of enhancers detected 
(Supplementary Fig. 22e, f).
As expected, consensus motifs of known key regulators are over-represented in 
corresponding facet-specific enhancers, for instance ETS, C/EBP, and NF-κB in monocyte-
specific enhancers, RFX and SOX in neurons, and HNF1 and HNF4a in hepatocytes 
(Supplementary Fig. 23). Notably, the AP1 motif appears to be enriched across all facets, 
perhaps associated with a general role for AP1 in regulating open chromatin19.
Expression clustering reveals ubiquitous enhancers
Hierarchical clustering of enhancers by facet expression revealed a small subset of 
enhancers (241 or 247, defined by primary cell or tissue facets, respectively) expressed in 
the large majority of facets (Supplementary Text, Supplementary Figs 24 and 25, and 
Supplementary Tables 12 and 13). Compared to other enhancers, the ubiquitous (u-) 
enhancers are 8 times more likely to overlap CGIs and they are twice as conserved 
(Supplementary Fig. 26a-c). U-enhancers overlap typical chromatin enhancer marks but 
have higher H3K4me3 signal (Supplementary Fig. 26d). Although they produce 
significantly longer ncRNAs than other enhancers (median 530 nt, P<1.5e-8, Mann-Whitney 
U test), the transcripts remain predominantly (~78%) unspliced and significantly shorter 
(P<4.2e-18, Mann-Whitney U test) than mRNAs (Supplementary Fig. 27-28), do not share 
exons with known genes, and are exosome-sensitive (Supplementary Fig. 14b). Therefore, it 
is unlikely that these are novel mRNA promoters. They are also highly enriched for P300 
and cohesin ChIP-seq peaks20 and RNAPII-mediated ChIA-PET signal21 compared to other 
enhancers (Supplementary Fig. 26d). These results suggest that u-enhancers comprise a 
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small but distinct subset of enhancers, which likely has specific regulatory functions utilized 
by virtually every human cell.
Linking enhancer usage with TSS expression
A major challenge is to link enhancers to their target genes21,22. Uniquely, FANTOM5 
CAGE allows for direct comparison between transcriptional activity of the enhancer and of 
putative target gene TSSs across a diverse set ofhuman cells. Based on pair-wise expression 
correlation, nearly half (40%) of the inferred TSS-associated enhancers (Methods) were 
linked with the nearest TSS, and 64% of enhancers have at least one correlated TSS within 
500kb. Several (10,260, 15.3%) associations are supported by ChIA-PET (RNAPII-
mediated) interaction data21, and the supported fraction increases with the correlation 
threshold (Supplementary Fig. 29a). The fraction of supported associations is 4.8-fold higher 
than that of associations predicted from DNase hypersensitivity correlations10 (20.6% vs. 
4.3%, at the same correlation threshold), indicating that transcription is a better predictor of 
regulatory targets than chromatin accessibility. Conserved sequence motifs and ChIP-seq 
peaks also co-occurred significantly in associated enhancer-promoter pairs (Benjami-
Hochberg FDR<0.05, binomial test), suggesting an additive or synergistic cooperation 
between enhancers and promoters at RNAPII foci.
On average, a RefSeq TSS was associated with 4.9 enhancers and an enhancer with 2.4 
TSSs and we observed different regulatory architectures around genes (Supplementary Fig. 
30). For example, at the beta-globin locus the CAGE expression patterns of four locus 
control region hypersensitive sites are highly correlated (Pearson's r between 0.88 and 0.98) 
with the expression of known target genes23,24 HBG2, HBD, and to some extent HBG1.
These observations call for computational models of enhancer regulation, in which multiple 
enhancers may work in concert to enhance the expression of a gene. To this end, we focused 
on 2,206 RefSeq TSSs for which the joint expression of nearby enhancers (the closest ten 
enhancers within 500kb) is highly predictive of the gene expression. Model shrinkage 
showed that in most cases, only 1-3 enhancers are necessary to explain the expression 
variance observed in the linked gene, and generally proximal enhancers are more predictive 
than distal ones (Fig. 6a, Supplementary Fig. 29b-d, and Supplementary Text). One 
hypothesis explaining the function of multiple enhancers driving the same expression pattern 
is that they might confer higher transcriptional output of a gene25,26. Indeed, the number of 
highly correlated (redundant) enhancers close to TSSs (Supplementary Methods Online) 
increased with the observed maximal TSS expression over all libraries (Fig. 6b), implying 
that these enhancers are redundant in terms of transcription patterns but additive in terms of 
expression strength. Expression redundancy is also common in genomic clusters of closely 
spaced enhancers (24% of 815 identified genomic clusters, Supplementary Table 15). These 
are associated with TSSs of genes involved in immune and defense responses and, as 
suggested by a previous study27, have a higher expression than other enhancer-associated 
genes (8-fold increase on average).
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Disease-associated SNPs are enriched in enhancers
Many disease-associated SNPs are located outside of protein-coding exons and a large 
proportion of human genes display expression polymorphism28. Using the NHGRI GWAS 
catalog29 and extending the compilation of lead SNPs with proxy SNPs in strong linkage 
disequilibrium (similar to refs. 30,31), we identified diseases/traits whose associated SNPs 
overlapped enhancers, promoters, exons and random regions significantly more than 
expected by chance (Fisher's Exact Test P<0.01, Supplementary Table 16). Disease-
associated SNPs were over-represented in regulatory regions to a greater extent than in 
exons (Fig. 6c). For many traits where enriched disease-associated SNPs were within 
enhancers, enhancer activity was detected in pathologically relevant cell types (Fig. 6d, and 
Supplementary Figs 31 and 32). Examples include Graves’ disease-associated SNPs 
enriched in enhancers that are expressed predominantly in thyroid tissue, and similarly 
lymphocytes for chronic lymphocytic leukemia. As a proof of concept, we validated the 
impact of two disease-associated regulatory SNPs within enhancers (Supplementary Fig. 
33).
CONCLUSIONS
The data presented here demonstrate that bidirectional capped RNAs, as measured by 
CAGE, are robust predictors of enhancer activity in a cell. Transcription is only measured at 
a fraction of chromatin-defined enhancers and few untranscribed enhancers show potential 
enhancer activity. This implies that many chromatin-defined enhancers are not regulatory 
active in that particular cellular state, but may be active in other cells of the same lineage32 
or are pre-marked for fast regulatory activity upon stimulation33. Of course, given the 
relative instability of enhancer RNAs some chromatin-defined sites may be active but fall 
below the limits of detection of CAGE.
Our results show that position-specific sequence signals upstream of the transcription 
initiation sites and the production of small, uncapped, RNAs immediately downstream is 
present at both enhancers and mRNA promoters, suggesting similar mechanisms of 
initiation. Previous studies (e.g. refs. 10,34,35) suggested that promoters and enhancers 
differ in motif composition. This view is not supported by the larger FANTOM5 dataset. 
Instead, the differences reflect the local GC content since transcribed enhancers tend to 
harbor GC-poor motifs like non-CGI promoters. Features distinguishing enhancers from 
mRNA promoters are: i) enhancer RNAs are exosome-sensitive regardless of direction while 
(sense) mRNAs have a longer half-life than their antisense counterpart; ii) enhancer RNAs 
are short, unspliced, nuclear and non-polyadenylated and iii) enhancers have downstream pA 
and 5’ splice motif frequencies at genomic background level similar to antisense PROMPTs, 
while mRNAs are depleted of termination signals and enriched for 5’ splice sites 11,12.
The collection of active enhancers presented here provides a resource that complements the 
activity of the ENCODE consortium7 across a much greater diversity of tissues and cellular. 
It has clear applications in human genetics, to narrow the search windows for functional 
association, and for the definition of regulatory networks that underpin the processes of 
cellular differentiation and organogenesis in human development.
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The FANTOM5 atlas is accessible from http://fantom.gsc.riken.jp/5/top. FANTOM5 CAGE, 
RNA-seq and sRNA data have been deposited in DDBJ (accession codes DRA000991, 
DRA001101). Genome browser tracks for enhancers with user-definable expression 
specificity-constraints can be generated at http://enhancer.binf.ku.dk. Here, pre-defined 
enhancer tracks and motif finding results are also deposited. Blood cell ChIP-seq data and 
CAGE data on exosome-depleted HeLa cells have been deposited in the NCBI GEO 
database (accession codes GSE40668, GSE49834).
Methods (full – for online materials)
CAGE data
Single molecule HeliScopeCAGE39 data was generated as described elsewhere 6. We used a 
set of 432 primary cell, 135 tissue, and 241 cell line samples that passed quality control 
measures of >500,000 Q20 Delve (Lassmann et al., in prep) mapped CAGE tags, RNA 
integrity and reproducibility (for further details, see ref 6).
Proof of concept analysis
We defined silent and active enhancers from ENCODE HeLa-S3, GM12878 and K562 broad 
peaks (Broad Institute, Bernstein), downloaded from the UCSC ENCODE repository, 
according to the co-existence of histone modifications H3K4me1, H3K27ac and 
H3K27me3. Active enhancers were defined as co-localized H3K4me1 and H3K27ac peaks 
with no H3K27me3 peak, while silent enhancers were considered loci with H3K4me1 and 
H3K27me3 peaks but no H3K27ac peak. Loci were filtered to be located distant to TSSs 
(500 bp) and exons (200 bp) of protein-coding genes, multi-exonic non-coding genes and 
mRNAs (from ENSEMBL, GENCODE (v10), RefSeq and UCSC, downloaded January 12, 
2012), and other lncRNAs from a gene-centric set derived from literature40 as well as 
manually annotated sense-antisense pairs (coding-noncoding and noncoding-noncoding 
sense-antisense pairs) with 5' EST and cDNA support, and 5' ESTs with no locus protein-
coding capacity. Transcriptional differences between active and silent enhancer sets were 
determined by comparing the average number of FANTOM5 CAGE tag 5’ ends from the 
same ENCODE cell lines (pooled triplicates) in a window +/− 300 bp around the H3K4me1 
peak mid points.
The active enhancer sets of HeLa-S3, GM12878 and K562 cells were then centered on 
proximal (within 200bp) P300 (Stanford, Snyder) ENCODE binding site peaks (joint P300 
and GATA1 (Yale) peaks for K562) to derive center positions. FANTOM5 CAGE data from 
the same ENCODE cell lines (pooled triplicates) were then overlaid these centered enhancer 
regions and the absence (0) and presence (1) of (one or more) CAGE tag 5’ ends in 10bp 
non-overlapping windows were determined and an average profile was calculated to assess 
the average bidirectional pattern of transcription at chromatin-derived enhancers.
Pooled CAGE data from all FANTOM5 libraries (described above) were further overlaid 
with these regions and a directionality score based on the aggregate of CAGE tags falling 
within +/− 300bp from the center positions were calculated to determine potential strand 
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bias. For comparison, we repeated the same calculations for genomic regions +/− 300bp 
around TSSs of RefSeq protein coding genes. Directionality was calculated as (F − R) / (F + 
R), where F and R is the sum of CAGE tags aligned on the forward and reverse strand, 
respectively. Directionality close to −1 or 1 indicates a unidirectional behavior while 0 
indicates perfectly balanced bidirectional transcription.
Positional cross correlations were calculated between reverse and forward CAGE tag 5’ ends 
at ChIP-seq derived active HeLa-S3 and GM12878 enhancer center positions (as determined 
by P300 peaks) +/−300 bp (max lag 300) to identify their most likely separation. Cross 
correlations were also calculated in 300 bp windows (max lag 150) flanking the enhancer 
centers between CAGE 5’ ends and ENCODE H2A.Z signals (from the same cell line) for 
HeLa-S3 and GM12878 as well as between CAGE 5’ ends and ENCODE GM12878 
nucleosome MNase-seq 5’ ends (9 pooled replicates). In the latter analysis, correlations 
were made using reads on the same strand. Pooled, unique CAGE tags (in which only one 
CAGE tag per bp was counted) were considered in all correlation analyses and enhancers 
were weighed according to the aggregated signal before subsequent averaging over lags not 
to make any library or enhancer have an undue influence.
Reporter activity of ENCODE enhancers in relation to transcriptional status
We used published8 results on a massively parallel reporter assay measuring the activity of 
ENCODE-predicted enhancers in HepG2 and K562 cells. All results on non-scrambled 
sequences were considered, regardless of the level of conservation. 198 out of 738 tested 
K562 enhancers and 307 out of 1136 tested HepG2 enhancers had significant enhancer 
reporter activity (as determined by the original publication). We determined the expression 
in 401bp windows centered on mid points of ENCODE-predicted enhancers using 
FANTOM5 CAGE from the same cell lines. We further calculated the false discovery rate 
after a minimum expression threshold in the interval [0,0.5] TPM, as the fraction of non-
significant enhancers among those fulfilling the expression cutoff.
Identification of bidirectionally transcribed loci
Bidirectionally transcribed loci were defined from a set of 1,714,047 forward and 1,597,186 
reverse strand CAGE tag clusters (TCs) supported by at least two CAGE tags in at least one 
sample (TCs defined in 6). Only TCs not overlapping antisense TCs were used. We 
identified 1,261,036 divergent (reverse-forward) TC pairs separated by at most 400 bp and 
merged all such pairs containing the same TC, while at the same time avoiding overlapping 
forward and reverse strand transcribed regions (prioritization by expression ranking), which 
resulted in 200,171 bidirectional loci (procedure illustrated in Supplementary Figure 6a). A 
center position was defined for each bidirectional locus as the mid position between the 
rightmost reverse strand TC and leftmost forward strand TC included in the merged 
bidirectional pair. Each bidirectional locus was further associated with two 200 bp regions 
immediately flanking the center position, one (left) for reverse strand transcription and one 
(right) for forward strand transcription, in a divergent manner. The merged bidirectional 
pairs were further required to be bidirectionally transcribed (CAGE tags supporting both 
windows flanking the center) in at least one individual sample, and to have a greater 
aggregate of reverse CAGE tags (over all FANTOM5 samples) than forward CAGE tags in 
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the 200 bp region associated with reverse strand transcription, and vice versa. These filtering 
steps resulted in 78,555 bidirectionally transcribed loci.
Expression quantification of bidirectionally transcribed loci and prediction of enhancers
We quantified the expression of bidirectional loci for each strand and 200 bp flanking 
window in each of the 432 primary cell, 135 tissue and 241 cell line samples separately by 
counting the CAGE tags whose 5' ends were located within these windows. The expression 
values of both flanking windows were normalized by converting tag counts to tags per 
million mapped reads (TPM) and further normalization between samples was done using the 
RLE normalization procedure in edgeR41. The number of CAGE tags aligned on ChrM was 
subtracted from the total number of aligned CAGE tags in each library before normalization. 
The normalized expression values from both windows were used to calculate a sample-set 
wide directionality score, D, for each enhancer over aggregated normalized reverse, R, and 
forward, F, strand expression values across all samples (Supplementary Fig. 6a); D = (F
−R) / (F+R). D ranges between −1 and 1 and specifies the bias in expression to reverse and 
forward strand, respectively (D=0 means 50% reverse and 50% forward strand expression, 
while abs(D) close to 1 indicates unidirectional transcription). A directionality score 
calculated from pooled data is a good estimate of sample directionality (Supplementary Fig. 
6b). Each bidirectional locus was assigned one expression value for each sample by 
summing the normalized expression of the two flanking windows.
Bidirectional loci were further filtered to have low, non-promoter-like, directionality scores 
(abs(D) < 0.8) and to be located distant to TSSs and exons of protein- and non-coding genes 
(see ‘Proof of concept analysis’ above for details). This resulted in a final set of 43,011 
putative enhancers.
We further tested whether the expression level for each sample and candidate enhancer was 
significantly greater than the genomic background (see construction of random genomic 
background regions below). A P-value was calculated for each enhancer expression value for 
each primary cell, tissue and cell line sample by counting the fraction of random genomic 
regions with greater expression level in the same sample. Enhancers with P-values less than 
0.001 and Benjamini-Hochberg adjusted FDR < 0.05 was considered transcribed in that 
sample. This analysis yielded binary expression values, which were used for constructing 
enhancer sets associated with each sample. In total, 38,554 enhancers were transcribed at a 
significant expression level in at least one primary cell or tissue sample. Below, we refer to 
this set as the ‘robust set’ of enhancers and indicate whenever it was used. For all analyses, 
we use the whole (‘permissive’) set of 43,011 enhancers if not otherwise mentioned.
Construction of random genomic background regions
We randomly sampled 100,000 genomic regions of 401 bp that were distal to TSSs and 
exons of known genes (same as the filtering procedure described above for bidirectionally 
transcribed loci). These were further filtered to not overlap with our set of 43,011 predicted 
enhancers, which yielded 98,942 random genomic regions whose expression levels were 
quantified and normalized in the same manner as described for bidirectional loci (above).
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Correlation between ENCODE epigenomic data and CAGE-defined enhancers
Using the UCSC ENCODE repository data (downloaded and pooled March 26 2012), we 
assessed the signal of RNA Polymerase II (RNAPII), the pooled transcription factor super 
track (all TFs), CCCTC-binding factor (CTCF), E1A binding protein P300, DNase I 
hypersensitive sites (DHSs) and two histone marks: H3K4me1 and H3K27ac around 
enhancers, TSSs and random genomic sites.
Large scale enhancer reporter validations
We randomly selected 125 CAGE-defined enhancers with significantly higher expression 
than random genomic regions in at least two out of three HeLa-S3 replicates. These were 
grouped according to Hela-S3 expression tertiles: (low (36), mid-level (41) and strong (46). 
These could be split up further according to overlap (mid position) with combined ENCODE 
(release Jan 2011) segmentations of Segway42 and ChromHMM43 chromatin state 
prediction: 25, 27, and 14 strongly, mid-level and lowly expressed CAGE enhancer 
overlapped ENCODE state ‘E’ (‘strong enhancer’) while 21, 16, and 22 strongly, mid-level 
and lowly expressed CAGE enhancer overlapped ENCODE state ‘TSS’.
We further randomly selected 26 and 15 untranscribed (negligible amount of overlapping 
FANTOM5 HeLa-S3 CAGE tags) 500bp regions centered on mid positions of HeLa-S3 E 
states and HeLa-S3 ENCODE DHSs. Two literature-derived44 HeLa-S3 positive enhancers 
and 4 random regions (see ‘Construction of random genomic background regions’) were 
used for comparison. For comparison, we also randomly selected 20 manually defined 
untranscribed HeLa-S3 chromatin-defined active enhancers (see ‘Proof of concept 
analysis’).
PCR primers for the amplification of enhancer and control regions were designed using the 
PerlPrimer tool45, and purchased from Operon Ltd. Primers included BamHI or SalI 
restriction sites for cloning and sequences are listed in Supplementary Tables 2 and 3. 
Control fragments ranged between 420-1452bp. Enhancer fragments usually included a 
500bp window around the mid point of our predicted enhancers and depending on the 
availability of unique primer sequences, enhancer fragments ranged between 470-840bp.
We inserted an EF1α basal promoter fragment into HindIII and NheI sites of the multiple 
cloning site in pGL4.10 (Promega) to construct a basal pGL4.10EF1α backbone. We next 
removed the the BamHI and SalI containing fragment located at downstream of the SV40 
late poly(A) signal of the original pGL4.10 vector backbone, and re-inserted the fragment at 
the SpeI site that is located upstream of the synthetic poly(A) signal/transcriptional pause 
site to generate modified versions of pGL4.10EF1α and pGL4.10 (see Supplementary 
Figure 9d).
Enhancer and control regions were PCR-amplified using KOD plus polymerase (TOYOBO) 
from HEK-293T gDNA, digested with BamHI and SalI (TAKARA BIO), and purified using 
the E-Gel® SizeSelect™ system (Life Technologies). Five μl of purified PCR products were 
ligated with 100 ng of the BamHI- and SalI-digested modified pGL4.10EF1α and pGL4.10 
plasmids using Ligation-high (TOYOBO), and transformed into DH5α competent cells 
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(TOYOBO). Correct insertion of the PCR products into the plasmids was checked by colony 
PCR. Vectors were purified using the QIAGEN Plasmid Plus 96 Miniprep Kit (QIAGEN).
HeLa-S3 cells (JCRB Cell Bank) were cultured in MEM (WAKO) supplemented with 10% 
FBS (NICHIREI BIOSCIENCE INC., Lot No. 7G0031), 100 Units/mL penicillin and 100 
μg/mL streptomycin (both Life Technologies). HepG2 Cells (RIKEN BRC) were cultured in 
DMEM (Life Technologies) supplemented with 10% FBS (NICHIREI BIOSCIENCE INC., 
Lot No. 7G0031), and MEM (WAKO) supplemented with 10% FBS (NICHIREI 
BIOSCIENCE INC., Lot No. 7G0031), 100 Units penicillin and 100 μg/mL streptomycin 
(Life Technologies). Cell lines were seeded into 96 well plates at a density of 7.5 × 103 cells/
well one day before transfection. Firefly luciferase reporter plasmids (190 ng) and 10 ng of 
pGL4.73 renilla luciferase plasmid (Promega) were co-transfected into HepG2 or HeLa-S3 
cells using Lipofectamine (Life Technologies) according to the manufacturer's instruction. 
Each transfection was independently performed three times. After 24 hours, the luciferase 
activities were measured by GloMax 96 Microplate luminometer (Promega) using the Dual-
glo luciferase assay system (Promega) according to the manufacturer's instruction.
Sequence motif analysis on global CAGE enhancer and promoter sets
To compare motif signatures characterizing bidirectionally transcribed enhancers 
(permissive set) with those of CAGE-defined promoters, we used the set of 184,827 robust 
human CAGE clusters defined by 6 separated into 61,322 CGI and 123,505 nonCGI-
associated clusters. We made further subsets of these CAGE clusters, contingent on their 
overlap with annotated TSSs from Refseq and Gencode. We merged overlapping extended 
CAGE clusters (−300, +50; based on the robust cluster set; average size nonCGI: 422 bp; 
average size CGI: 544 bp) contingent on CGI status and subtracted CAGE cluster regions 
that overlapped with extended enhancers (mid position +/− 200 bp).
This created five sets of regions representing non-overlapping bidirectional enhancers, 
nonCGI promoters and CGI promoters (annotated and full sets for the two latter ones). Motif 
enrichment was analyzed using HOMER36 version 3, a suite of tools for motif discovery and 
next-generation sequencing analysis (http://biowhat.ucsd.edu/homer/). Sequences of the 
three region sets (enhancers, nonCGI and CGI promoters) were compared to equal numbers 
of randomly selected genomic fragments of the average region size, matched for GC content 
and autonormalized to remove bias from lower-order oligo sequences. After masking 
repeats, motif enrichment was calculated using the cumulative binomial distribution by 
considering the total number of target and background sequence regions containing at least 
one instance of the motif. One hundred motifs were searched for a range of motif lengths 
(7-14 bp) resulting in a set of 800 de novo motifs per set. After filtering redundant motifs, 
the top 50 motifs resulting from each search were combined, remapped and ranked 
according to enrichment (depletion) in the enhancer set. In parallel, we also used HOMER to 
calculate the enrichment of ChIP-seq derived known transcription factor motifs. Motif 
collections including search parameters are deposited in a web database at http://
enhancer.binf.ku.dk. Histograms of PhastCons scores were generated using the annotation 
tool in HOMER.
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Analysis of splice site and termination signals downstream of CAGE enhancer TSSs and 
promoter TSSs
To identify motifs downstream of TSSs potentially differing between the structurally related 
bidirectionally transcribed enhancer TSSs and nonCGI-associated promoter TSSs, we 
extracted 600bp regions downstream of each TSS and performed comparative de novo motif 
searches using HOMER. Here, we analyzed one set using the other set as background 
(corrected for region size, matched for GC content and autonormalized) to calculate motif 
enrichment only on the given strand. The top motif enriched downstream of nCGI promoters 
was the 5’-splice site motif. Genomic distributions of the enriched splice site motif, as well 
as the AATAAA termination signal were generated using HOMER.
RNA-seq samples and library preparation
Prior to preparation of sequencing libraries, rRNA was removed by poly(A)+ selection 
(CD19+ B-cells, CD8+ T-cells, 500 ng) or rRNA depletion (fetal heart, 1 ug). Poly(A)+ 
selection was done twice by using Dynabeads Oligo(dT)25 (Life Technologies) according to 
the manufacturer's manual. rRNA depletion was done by using Ribo-Zero rRNA removal kit 
(Epicentre, Illumina) according to the manual. The treated RNA was dissolved in 20 μL 
water.
The pretreated RNA was then fragmented by heating at 70°C for 3.5 min in fragmentation 
buffer (Ambion), followed by immediate chilling on ice and addition of 1 μl of Stop 
solution. Fragmented RNA was purified with the RNeasy MinElute kit (Qiagen) following 
the instructions of the manufacturer except 675 μL of 100% ethanol is used in step two, 
instead of 500 μl. Purified RNA was dephosphorylated in phosphatase buffer (New England 
Biolabs) with 5 U of Antarctic phosphatase (New England Biolabs) and 40 U of RNaseOut 
(Life Technologies) at 37°C for 30 min followed by 5 min at 65°C. After chilling on ice 
RNA was phosphorylated by addition of the following reagents; 5 μl of 10× PNK buffer, 20 
U of T4 polynucleotide kinase (New England Biolabs), 5 μl of 10 mM ATP (Epicentre, 
Illumina), 40 U of RNaseOut, 17 μl of water. The reaction was incubated at 37°C for 60 min. 
Phosphorylated RNA was purified with the RNeasy MinElute kit (Qiagen) as described 
above. Purified RNA was concentrated to 6 μl by vacuum centrifugation on a SpeedVac 
(Eppendorf). One μl of 2 μM pre-adenylated 3’ DNA adaptor, 5’-App/ATC TCG TAT GCC 
GTC TTC TGC TTG-3' was added to the concentrated RNA. After incubation at 70°C for 2 
min followed by chilling on ice for 2 min, the following reagents were added to ligate the 
adapter at the 3’ end of the RNA; 1 μl of 10× T4 RNA ligase 2 truncated buffer, 0.8 μl of 
100 mM MgCl2, 20 U of RNaseOUT and 200 U of RNA ligase 2 truncated (New England 
Biolabs). After the incubation at 20°C for 60 min, 1 μl of heat-denatured 5 μM 5’ RNA 
adapter, 5’-guu cag agu ucu aca guc cga cga ucg aaa-3’ was ligated with 3’ adapter ligation 
products with 20 U of T4 RNA ligase 1 (New England Biolabs) and 1 μl of 10 mM ATP 
(New England Biolabs) at 20°C for 60 min. 4 μl of adapter ligated RNA was mixed with 1 μl 
of 20 μM RT Primer, 5’-CAA GCA GAA GAC GGC ATA CGA-3’, followed by incubation 
at 70°C for 2 min, and immediately kept on ice. RT reaction was done with 2 μl 5× Prime 
Script buffer, 1 μl of 10 mM dNTP, 20 U of RNaseOUT and 200 U of PrimeScript Reverse 
Transcriptase (TakaraBIO) at 44°C for 30 min. The cDNA product was amplified by PCR 
with 10 μl of 5× HF buffer, 1.25 μl of 10 mM each dNTP mix, 2 μl of 10 μM FWD primer, 
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5’-AAT GAT ACG GCG ACC ACC GAC AGG TTC AGA GTT CTA CAG TCC GA-3’, 2 
μl of RT primer and 1 U of Phusion High-Fidelity DNA Polymerase (New England Biolabs). 
PCR was carried out in a total volume of 50 μl with the following thermal program; 98°C for 
30 sec, 12 PCR cycles of 10 sec at 98°C, 30 sec at 60°C, and 15 sec at 72°C, followed by at 
72°C for 5 min and then kept at 4°C. Remaining PCR primers were removed twice by using 
1.2 volumes of AMPure XP beads (Beckman Coulter). The resulting libraries were checked 
for size and concentration by BioAnalyzer (Agilent) using the High-Sensitivity DNA Kit 
(Agilent). Qualified sequencing libraries were loaded on the HiSeq2000 (Illumina) using the 
custom sequencing primer, 5’-CGA CAG GTT CAG AGT TCT ACA GTC CGA CGA TCG 
AAA-3’.
All RNA-seq samples profiled in this study were also profiled in the FANTOM5 
promoterome manuscript and are described in detail there 6. Briefly all human samples used 
in the project were either exempted material (available in public collections or commercially 
available), or provided under informed consent. All non-exempt material is covered under 
RIKEN Yokohama Ethics applications (H17-34 and H21-14). For the samples profiled by 
RNA-seq, the human fetal heart RNA was purchased from Clontech (Cat no.636583). 
CD19+ B-cells and CD8+ T-cells were isolated using the pluriBead®system (huCD4/CD8 
cascade and huCD19 single; PluriSelect). RNA was then extracted using the miRNeasy kit 
(Qiagen).
RNA-seq mapping and transcript assembly
Single-end 100bp long reads from libraries originating from the similar cell sources (all six 
“CD19+ B cells” libraries, all six “CD8+ T cells” libraries and one “Fetal heart” library) 
were processed together via the Moirai pipeline (Hasegawa et al., manuscript in 
preparation). The processing steps implemented within the Moirai pipeline included 1) raw 
sequenced reads PolyA tail and “CTGTAGGCACCATCAAT” adaptor clipping using 
FASTQ/A Clipper from FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/), 2) 
removal of sequenced reads containing “N” and sequences similar to ribosomal RNA using 
rRNAdust version 1.02 (Lassmann et al., manuscript in preparation), and 3) mapping the 
resulting reads against the hg19 human genome using TopHat46 (version 1.4.1) using both 
TopHat de novo junction finding mode and known exon-exon junctions extracted from 
GENCODE V10, with all the other parameters set to their default values. Mapped reads 
flagged as PCR duplicates were removed and the remaining TopHat aligned reads were then 
assembled using Cufflinks47 (version 1.3.0) with Cufflinks parameters set to their default 
values.
Assessment of lengths of RNAs emanating from enhancers and promoters
All Cufflinks assembled transcripts, whose 5’ends, regardless of strand, were located within 
the outer boundaries of CAGE enhancers or, on the same strand, within 200bp (upstream or 
downstream) of a GENCODE (v10) protein-coding TSS were considered for further 
analysis. For these Cufflinks transcripts we calculated their (intron-less) RNA length, 
(possibly intron-containing) genomic length as the genomic distance between their 5’ and 3’ 
ends, as well as their number of exons. Exons of Cufflinks transcripts with 5’ ends in 
enhancers were further checked for at least 50% (reciprocal) overlap with exons of 
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GENCODE (v10) known, level 1, protein-coding genes and lincRNAs. We repeated the 
same analysis specifically for u-enhancers.
Small RNA library preparation and mapping
Short RNA-seq sequencing libraries were prepared as 24-plex using the TruSeq Small RNA 
Sample Prep Kit (Illumina) following the manufacturer's manual. All starting sources were 1 
μg of total RNA. The prepared sequencing libraries were loaded on a HiSeq2000 (Illumina). 
All samples profiled in this study were also profiled in the FANTOM5 promoterome paper6 
and are described in detail there. Briefly, all human samples used in the project were either 
exempted material (available in public collections or commercially available), or provided 
under informed consent. All non-exempt material is covered under RIKEN Yokohama 
Ethics applications (H17-34 and H21-14). For the samples profiled by sRNA-seq, the human 
fetal heart RNA was purchased from Clontech (Cat no.636583). CD19+ B-cells and CD8+ 
T-cells were isolated using the pluriBead®system (huCD4/CD8 cascade and huCD19 single; 
PluriSelect). RNA was then extracted using the miRNeasy kit (Qiagen).
Short RNAs were profiled using the Truseq protocol from Illumina, using an 8-plex. The 8-
plex was first split by barcode and the resulting FASTQ sequences trimmed of the 3' adapter 
sequence. Sequences with low quality base N were removed. Ribsomal RNA sequences 
were then removed using the rRNAdust program. Remaining reads were then mapped using 
BWA version is 0.5.9(r16) and multimappers were randomly assigned.
Analysis of small RNAs at enhancer TSSs and promoter TSSs
5’ and 3’ ends of mapped sRNAs as well as pooled CAGE 5’ ends were overlaid windows of 
601 bp centered on forward strand summits of enhancer-defining CAGE tag clusters and 
sense strand summits in promoters of RefSeq protein-coding genes. The average cross-
correlation between CAGE 5’ ends and sRNA 3’ ends were calculated in these windows 
allowing a max lag of 300. For footprint plots, reads mapping to the same genomic locations 
were only counted once not to make any library or genomic region have an undue influence.
HeLa cells culturing and hMTR4 depletion
HeLa cells were grown in DMEM medium supplemented with 10% fetal bovine serum at 
37°C and 5% CO2. siRNA-mediated knockdown of either EGFP(control), and hMTR4 
(SKIV2L2) were performed using 22 nM of siRNA and Lipofectamin2000 (Invitrogen) as 
transfecting agent. A second hit of 22 nM siRNA was given after 48 h. Cells were harvested 
an additional 48 h after the second hit, and protein depletion was verified by western blotting 
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HeLa CAGE library preparations and data processing
CAGE libraries were prepared from 5 μg of total RNA purified from 2×106 HeLa cells using 
the Purelink mini kit (Ambion) with 1% 2-Mercaptoethanol (Sigma) and on-column DNAse 
I treatment (Ambion) as recommended by manufacturer. CAGE libraries were prepared 
according as described previously49. Prior to sequencing four libraries with different 
barcodes were pooled and applied to the same sequencing lane. The libraries were 
sequenced on a HiSeq2000 instrument (Illumina). To compensate for the low complexity in 
5’end of the CAGE libraries 30% Phi-X spike-in were added to each sequencing lane as 
recommended by Illumina. CAGE reads were assigned to their respective originating sample 
according to identically matching barcodes. Assigned reads were trimmed to remove linker 
sequences and subsequently filtered for a minimum sequencing quality of 30 in 50% of the 
bases using the FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/). Mapping to the 
human genome (hg19) was performed using Bowtie50 (version 0.12.7), allowing for multiple 
good alignments and subsequently filtering for uniquely mapping reads. Reads that mapped 
to unplaced chromosome patches or chrM were discarded.
Assessment of degradation rates of RNAs emanating from CAGE enhancers and 
promoters
Bidirectionally transcribed loci were identified in the same way as with pooled FANTOM5 
CAGE libraries (see ‘Identification of bidirectionally transcribed loci’ and ‘Expression 
quantification of bidirectionally transcribed loci and prediction of enhancers’ above) from 
tag clusters (as defined in 51) derived from pooled HeLa CAGE (mock treated control, 
hMTR4) libraries. From 5,892 bidirectional loci distant to TSSs and exons, 4196 were 
predicted to be enhancers based on balanced directionality of transcription of which 3,896 
had significantly greater expression than random genomic regions in at least one library. 
These were then overlapped with the whole set of FANTOM5 CAGE enhancers to estimate 
the fraction of unseen transcribed enhancers.
The expression fold change of HeLa depleted of hMTR4 compared to mock treated control 
were assessed and compared between expressed HeLa CAGE enhancers, promoters of 
RefSeq protein-coding genes in general and broken up into CpG and non-CpG promoters, 
and ubiquitous FANTOM5 CAGE enhancers.
We further calculated the average footprints of H3K4me1, H3K4me2 and H3K27ac from 
ENCODE (Broad, Bernstein) signal files in 601 bp windows centered on mid points of 
enhancers identified in HeLa cells and those that were novel in hMTR4-.
Purification of blood cell types
Peripheral blood mononuclear cells were isolated from leukapheresis products of healthy 
volunteers by density gradient centrifugation over Ficoll/Hypaque (Biochrom AG, 
Germany). Collection of blood cells from healthy donors was performed in compliance with 
the Helsinki Declaration. All donors signed an informed consent. The leukapheresis 
procedure and subsequent purification of peripheral blood cells was approved by the local 
ethical committee (reference number 92-1782 and 09/066c). CD4+ cells were enriched using 
magnetically labeled human CD4 MicroBeads (Miltenyi Biotec,Germany) and the Midi-
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MACS system (Miltenyi Biotec). The CD4+ fraction was stained with CD4 FITC (Becton 
Dickinson, cat no. 345768), CD25 PE (Becton Dickinson, cat no. 341011) and CD45RA 
APC and CD3+CD4+CD25− T cells were sorted on a FACS-Aria high-speed cell sorter (BD 
Biosciences, Germany). CD8+ cells were enriched using magnetically labeled human CD8 
MicroBeads (Miltenyi). The CD8+ fraction was stained with CD3 FITC (Becton Dickinson, 
cat no 345763) and CD8 APC (Becton Dickinson, cat no. 345775) and sorted for 
CD3+CD8+ T cells. CD19+ and CD56+ cells were enriched from the CD8− fraction using 
magnetically labeled human CD19 and CD56 MicroBeads (Miltenyi). Enriched cells were 
stained with CD3 FITC (Becton Dickinson,cat no. 345763), CD19 PE (Becton Dickinson, 
cat no. 345777) and CD56 APC (Becton Dickinson, cat no.341027) and sorted into 
CD3+CD19+ B cells and CD3+CD56+ NK cells. Purification of blood monocytes is 
described elsewhere52.
Generation of ChIP data for blood cells
Chromatin was obtained from CD4+CD25− T cells, CD8+ T cells, CD19+ B cells, and 
CD56+ NK cells of two healthy male donors each. Chromatin immunoprecipitation (ChIP) 
for H3K4me1 and H3K27ac and library construction were done essentially as described 
elsewhere52. Sequence tags were mapped to the current human reference sequence 
(GRCh37/hg19) using Bowtie50 and only uniquely mapped tags were used for downstream 
analyses. H3K4me1 and H3K27ac ChIP-seq data for CD14+ monocytes was generated 
elsewhere52. Complementary DNase hypersensitivity sequencing data was obtained from the 
Epigenetics Roadmap project (www.roadmapepigenomics.org) and mapped as above. Blood 
cell ChIP-seq data have been deposited with the NCBI GEO database (accession code 
GSE40668) and UCSC Genome Browser track hub data of the entire blood cell data set can 
be found at http://www.ag-rehli.de/NGSdata.htm. Also see Supplementary Table 4.
Clustering of blood cell CAGE and epigenetics data
CAGE samples corresponding to CD4+, CD8+, B cells, NK cells and monocytes were 
selected in triplicates from among the set of primary cell samples. Based on the total set of 
43,011 permissive enhancers, a subset of 6,609 blood-expressed enhancers was defined as 
being significantly expressed above genomic background (described above) in at least two of 
the triplicate samples for at least one blood cell type. This subset of enhancers was clustered 
for heat map visualization using complete linkage agglomerative hierarchical clustering 
based on enhancer usage per cell type (binary matrix) and Manhattan distance.
Enhancers were defined as being specifically expressed in one blood cell type if having a 
pairwise log2 fold change >1.5 with respect to the other four blood cell types. The fold 
change was calculated based on the mean expression over triplicate samples per cell type. 
Footprints for DNase I hypersensitivity (DHS), H3K4me1 and H3K27ac were calculated per 
cell type-specific enhancer set and cell type by extension of reads to 200 bp and overlap 
aggregation for a window of +/− 1kb around enhancer midpoint as the mean TPM signal 
over all enhancers in that specific subset.
Peak-calling was done using MACS253 on pooled data for DHS, H3K4me1 and H3K27ac. 
Per cell type, peaks were regarded as significant if the peak summit fell within the upper 1 
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percentile of the background signal (max values in 92,604 random 1kb non-TSS non-
enhancer regions). DHS regions were defined as +/−500 bp around peak summits. Since 
ChIP-Seq signals for H3K4me1 and H3K27ac often form bimodal peaks around enhancer 
sites, peak regions were defined as merged regions resulting from overlapping +/− 500 bp 
regions around MACS2 called peak summits.
Transient enhancer-reporter assays in blood cells
Selected blood cell type-specific enhancer regions (ranging from 800-1200 bp) were PCR-
amplified from human genomic DNA and cloned directly into the CpG-free pCpGL-
CMV/EF1 vector 54,55 replacing the CMV enhancer with the DMR regions. Primer 
sequences are given in Supplementary Table 5. All inserts were verified by sequencing. For 
transient transfections, plasmids were isolated and purified using the EndoFree Plasmid Kit 
(Qiagen). Each luciferase construct was transiently transfected into three model cell lines 
(the monocytic THP-1 cell line, the Jurkat T cell line, and the B cell lymphoma cell line 
DAUDI). THP-1 and DAUDI cells were transfected using DEAE-dextran with 200 ng 
reporter plasmid and 10 ng Renilla control vector essentially as described56. Jurkat cells 
were transfected as described elsewhere54. The transfected cell lines were cultivated for 48 
h, harvested, and cell lysates were assayed for firefly and Renilla luciferase activity using 
the Dual Luciferase Reporter Assay System (Promega) on a Lumat LB9501 (Berthold, 
Wildbach, Germany). Firefly luciferase activity of individual transfections was normalized 
against Renilla luciferase activity. Transfections correspond to at least three independent 
experiments measured in duplicates.
To correct enhancer activity for the amount of read-through that is potentially generated 
from the enhancer TSS, we additionally generated constructs lacking the basal EF1α 
promoter for all B cell-specific constructs. Relative luciferase activities generated by read-
through activity were subtracted from the activity of enhancer/EF1 constructs to reveal ‘true’ 
enhancer activities of individual regions. To further determine the position and activity of 
reporter TSS, 5’ RACE-PCR for the luciferase gene was performed as follows: RNA of 
transfected DAUDI cells was reverse transcribed using the SMARTer™ RACE cDNA 
Amplification Kit (Clontech, France) according to the manufacturers’ instructions. Rapid 
Amplification of luciferase 5’ cDNA ends (5’ RACE) was performed with the Advantage 2 
Polymerase System (Clontech) and a LUC specific primer (5’-CAT GGC TTC TGC CAG 
CCT CAC AGA CAT C-3’) using the recommended touchdown-PCR program. 15μl of the 
PCR products were analyzed by agarose gel electrophoresis (2.5%). In addition, fragments 
were cloned using the StrataClone PCR cloning Kit (Agilent) according to the 
manufacturers’ instructions and sequenced (Life Technologies, Germany).
Mass spectrometry analysis of bisulfite-converted DNA
For the set of genomic regions that were also used in transient enhancer-reporter assays, 
PCR primers were designed using the MethPrimer web tool57 and purchased from Sigma-
Aldrich (Munich, Germany) (for sequences see Supplementary Table 7). Sodium bisulfite 
conversion was performed using the EZ DNA methylation kit (Zymo Research, California, 
USA) using 200-1000 ng of genomic DNA from CD4+CD25− T cells, CD8+ T cells, 
CD14+ monocytes, CD19+ B cells, and CD56+ NK cells (two donors each) and an 
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alternative conversion protocol. Amplification of target regions was followed by SAP 
treatment, reverse transcription and subsequent RNA base-specific cleavage (MassCLEAVE, 
San Diego, CA) as previously described58. Cleavage products were loaded onto silicon chips 
(SpectroCHIP, CA) and analyzed by MALDI-TOF mass spectrometry (MassARRAY 
Compact MALDI-TOF, U.S.Sequenom, San Diego, CA). Methylation was quantified from 
mass spectra using the Epityper software (Sequenom, U.S), and averaging methylation levels 
of CpG dinucleotides located in the central DNase hypersensitive (nucleosome-free) region 
that is flanked by CAGE clusters. The methylation data for individual CpGs are provided in 
Supplementary Table 8.
Definition of expression facets and differentially expressed ‘specific’ facets
Cell and UBERON ontology term mappings were extracted from the FANTOM5 sample 
ontology 6 for primary cell and tissue samples, respectively, using indirect and direct ‘is_a’ 
and ‘part_of’ relationships. Ontology terms were manually selected to construct groups 
(facets) of samples that were mutually exclusive and to cover as broad histological and 
functional annotations as possible. 362 primary cell samples and 138 tissue and whole blood 
samples were grouped into 69 cell type facets and 41 organ/tissue facets, respectively (the 
groupings of samples into facets are provided in Supplementary Tables 10 and 11). A few 
samples were ignored because they were difficult to assign to a facet with certainty, which 
means that the number of samples within facets is slightly lower than the total number of 
samples.
For each facet, we defined a set of robustly expressed enhancers from the union of 
significantly expressed enhancers (see calculation of expression significance above) 
associated with each contained sample.
For motif search (see below), we identified the set of robust enhancers that were 
significantly deviating between facets using Kruskal-Wallis rank sum tests (Benjamini-
Hochberg FDR < 0.05) and performed pair wise post-hoc tests (Nemenyi-Damico-Wolfe-
Dunn (NDWD) test59,60 using the R coin package61 to identify enhancers with significant 
differential expression (Bonferroni single-step adjusted P < 0.05) between facets. Cell type 
facets and tissue/organ facets were analyzed separately. Each enhancer was considered 
differentially expressed in a facet with at least one pair-wise significant differential 
expression and overall positive standard linear statistics. This procedure means that we, for 
each robust enhancer, selected the facets, if any, with strong overall differential expression 
compared to all other facets. It should be noted that differential expression in this sense is 
not equivalent to facet-specific (exclusive) expression.
Specificity and usage level analysis
For each robust enhancer, we calculated a ‘specificity’ score across cell type and organ/
tissue facets. The specificity score was defined to range between 0 and 1, where 0 means 
unspecific (ubiquitously expressed across facets) and 1 means specific (exclusively 
expressed in one facet).
In detail, specificity(X) = 1 – (entropy(X) / log2(N) ), where X is a vector of sample-average 
expression values for an enhancer over all facets (cell types and organs/tissues were 
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analyzed separately) and N its cardinality (|X|, the number of facets). The same calculations 
were done for TPM and RLE normalized CAGE-derived expression levels of RefSeq 
protein-coding gene promoters (TSS +/− 500 bp).
In order to visualize the complexity and specialization of facets according to usage and 
specificity score of enhancers and genes, we counted the frequency of facet-used enhancers 
(significantly expressed in at least one contained sample) and gene promoters (≥ 1 TPM in at 
least one sample) with a specificity score in any of 20 bins distributed between 0 and 1. The 
number of robustly expressed enhancers and genes per sample were normalized to enhancers 
and genes per million mapped tags, utilizing the total number of mapped CAGE tags in each 
sample, and further log-transformed. The counts per million mapped tags were visualized in 
box plots split by facet (only facets with more than one contained sample were considered).
Motif analysis on differentially specific enhancer sets
To identify and compare motif signatures characterizing facet-specific enhancers (permissive 
set) we applied de novo motif analyses. Motif enrichment was analyzed using HOMER. 
Enhancer regions (400bp) were compared to ~50,000 randomly selected genomic fragments 
of the same region size, as described above. Twenty-five motifs were searched for a range of 
motif lengths (7-14 bp) resulting in a set of 200 de novo motifs per set, which was further 
filtered to remove redundant motifs. In parallel, we also used HOMER to calculate the 
enrichment of ChIP-Seq derived motifs. Motif collections including search parameters for 
all facets are deposited in the web database at http://enhancer.binf.ku.dk. Known 
transcription factor motifs were used to compare motif enrichment between facets.
Hierarchical clustering of samples
Tissue and primary cell samples mapped to ontology facets were clustered by complete 
linkage agglomerative hierarchical clustering based on Jensen-Shannon (JS) divergence59. In 
detail, expression values for all enhancers in the permissive set were normalized to sum to 1 
for each sample and the square root (proper distance metric) of all pair wise JS divergences 
between samples was calculated. Manually selected clades of samples were analyzed for 
differential expression in a similar way as was done for facets (see above). In summary, 
differentially expressed enhancers (robust set) were identified by Kruskal-Wallis rank sum 
tests (Benjamini-Hochberg FDR<0.05) and subsequent NDWD post-hoc tests were 
performed to find all significant pair wise differences (Bonferroni single-step adjusted 
P<0.05) between clades.
Hierarchical clustering of enhancers
We used matrices describing each enhancer expression in TPMs for each facet (primary cell 
facets and tissue facets were clustered independently) and clustered these by complete 
linkage agglomerative hierarchical clustering using Euclidan distances, as implemented in 
the gputools R package62, and ran these in parallel on a GTX960 Nvidia GPU. Due to 
limited memory in the GPU, we reduced the matrices to enhancers with total expression > 
2.5 TPM in the primary cell set and >0.6 TPM in the tissue/organ set, resulting in sets of 
roughly 22.500 enhancers each. To make sure these results were stable, we also explored 
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normalization using fold change vs. background in each facet instead of TPM normalization, 
which resulted in very similar results (data not shown).
We then used the cutree method to select 5 sub-clusters in each tree, starting from the root. 
Enhancers in each set were then extended +−300 nt from their midpoints, and CpG islands 
and observed / expected CpG ratios were calculated. The resulting sub-clusters broke up 
enhancers into 201 and 247 ubiquitous enhancers (u-enhancers) defined by cell type and 
tissue facets, respectively, (these sets intersect by 106 enhancers) and non-ubiquitous 
enhancers. To summarize the features of u-enhancers in terms of expression width and 
variance, identified in a single plot, we used those enhancers falling into u-enhancer group 
from the tissue clustering. We then plotted the mean TPM over all tissue facets, as well as 
the coefficient of variation (expression variance over all tissue facets scaled by mean 
expression). Then we repeated this for the remaining enhancers (non-u-enhancers).
Zebrafish reporter transgenesis experiments
We selected enhancers for validation based on human-zebrafish conservation (>70% 
sequence identity over 100 nt, hg19 vs DanRer7) in order to take into account the large 
evolutionary separation between the two species, and selected enhancers that were only 
expressed in a subset of tissues/cells. We did not take epigenetic data (ChIP/DHS etc.) into 
consideration. We also selected three negative control regions, chosen randomly from the 
human genome with the following constraints: low conservation with zebrafish and no other 
enhancer-selective feature, that is, no DNase hypersensitivity, no H3K4me1 or H3K27ac 
signals and CAGE signal only at noise levels.
Selected human enhancers (CRE1-5) were amplified from human genomic DNA using 
primers (Supplementary Table 9). PCR products were purified using NucleoSpin Gel and 
PCR Clean-up Kit (Macherey Nagel) and were digested using appropriate enzymes (listed in 
Supplementary Table 9). Human enhancers were cloned into EcoRV/SpeI or HindIII/EcoRI 
sites of pDB896 vector (gift from Darius Balciunas) upstream of zebrafish gata2 
promoter63,64 and YFP reporter gene. Plasmid DNA was purified using NucleoBond® Xtra 
Midi Kit (Macherey Nagel) and quality checked by sequencing before injections.
Zebrafish stocks (Danio rerio) were kept and used according to Home Office regulations 
(UK) at the University of Birmingham. For these experiments wild-type fish (AB* strain) 
were used. Adults were crossed pairwise and eggs were collected 10-15 minutes after 
fertilization. Microinjection solutions contained 30 ng/μl of plasmid DNA, 0,2% of phenol 
red (Sigma) and 15 ng/μl of Tol2 mRNA transcribed in vitro from pCS2:Tol2 plasmid using 
mMESSAGE machine SP6 Kit (Ambion). Injections were performed through the chorion 
and into the cytoplasm of zygotes using an analogue pressure-controlled microinjector 
(Tritech Research). More than 200 eggs were injected per construct and experiments were 
replicated at least three times. Embryos were kept according to65 in E3 Medium containing 
50 ng/ml of gentamicin (Fisher Scientific) and 0,03% phenylthiourea (PTU, Sigma) in an 
incubator at 28.5°C.
Injected embryos were screened during the first 5 days post-fertilization using a Nikon 
SMZ1500 fluorescence stereomicroscope. Specific expression patterns were documented at 
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48 hpf and levels of expression were quantified by counting the number of embryos showing 
enhancer-specific expression. In order to control for overall background activity from the 
construct (ie, promoter, backbone) an empty pDB896 vector containing gata2 zebrafish 
promoter linked to the reporter gene but lacking an enhancer sequence was used. Any tissue-
specific enrichment shown by enhancer-containing vectors over the activity shown by the 
empty control vector was considered enhancer-specific. Additionally, three negative regions 
were also cloned to check the specificity of the enhancer selection process. These regions 
were chosen randomly from the human genome to have low conservation with zebrafish and 
no other enhancer-selective feature, that is, no DNase I hypersensitivity, no H3K4me1 or 
H3K27ac signals and CAGE signal only at noise levels. In parallel, 5 selected human 
enhancers were also analyzed. See Supplementary Table 9 for a summary of zebrafish 
validations, including expression patterns, signal strengths and primers.
Analysis of cohesin data
We used MCF7 cell ChIP experiments with antibodies targeting STAG1 and RAD21 
proteins, downloaded from the Short Read archive (accession ERR011980, ERR011982). 
These were mapped using Bowtie50 with standard settings but discarding non-unique hits, 
and peak-called using MACS53 with default settings. We then used the intersection between 
peak sets as proxy binding sites for the cohesin complex.
Linking TSSs and enhancers by expression correlations
We identified all intra-chromosomal enhancer-promoter pairs (470,315 cases, permissive set 
of enhancers and unique locations of RefSeq protein-coding gene transcript TSSs +/− 500 
bp) within 500 kb, in which the TSS was expressed >1 TPM in at least one sample, and 
performed Pearson correlation tests between the expression of such pairs: 64% of enhancers 
had at least one significant association (Benjamini-Hochberg FDR <= 1e-5) within that 
distance. On average, a TSS was associated with 4.9 enhancers and an enhancer with 2.4 
TSSs.
Next, we identified which predicted associations were supported by ENCODE ChIA-PET 
(via RNAPII (MMS-126R)) interaction data21 from four ENCODE cell lines (HCT-116, 
HeLa-S3, K562, MCF-7) by requiring an overlap of both enhancer and promoter in both 
(and different) sites of a ChIA-PET interaction pair. An association was considered 
supported if it overlapped in this way with any cell line replicate of interactions.
For comparison, the fraction of 1,672,958 published10 predicted enhancer-promoter 
associations derived from DNase data supported by ENCODE ChIA-PET interaction data 
was calculated.
Analysis of genomic clusters of densely positioned enhancers
By pairwise distance calculations between CAGE enhancers, we identified clusters of 
densely positioned enhancers in the genome. 815 regions of length >=2kb containing >2 
enhancers were identified. Of these, 198 regions contained enhancers whose average 
pairwise expression correlation (Pearson's r) were >=0.75. The expression of associated 
Refseq genes (see ‘Linking TSSs and enhancers by expression correlations’) as well as their 
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enrichment of gene ontology biological process terms (via the DAVID tool66) were 
compared to that of genes associated with non-clustered enhancers.
Inferring regulatory architectures by multiple linear regression
Multiple linear regression was performed for all 25,144 expressed (max TPM >1) RefSeq 
TSSs with at least ten FANTOM5 CAGE-defined enhancers within 500 kb. Enhancers were 
ranked by proximity to the TSS and the expression values across all samples of the ten 
closest were used as predictor variables in a model with the TSS expression as response 
variable. The expression data of enhancers and TSSs were centered and rescaled. 2,206 TSS 
models, considering in total 11,386 enhancers, with R2 ≥ 0.5 were considered for further 
analyses. We also fitted a simple linear regression model using each enhancer as predictor 
variable on their own, in order to compare the predictive power of a single enhancer to the 
power of using all ten. We defined a new measure of ‘proportional contribution’ to the 
variance explained as the ratio between simple linear regression r2 and multiple linear 
regression R2, for each enhancer among the ten considered for each TSS. This measure 
yielded highly similar ranking results of enhancers as the R2 contribution averaged over 
orderings among regressors67,68 and R2 decorrelation decomposition67,69 (data not shown), 
implemented in the ‘relaimpo’ R package37,69 (lmg and car methods, respectively). We used 
ranking of enhancers according to proportional contribution and within-model enhancer-
enhancer correlations to identify TSSs with different enhancer architectures. Redundant 
enhancers were identified for TSSs that had enhancers that were, by proportional 
contribution, ranked second and onwards with at least some proportional contribution (>0.2) 
and high correlation (Pearson's r>0.7) with any other of the nine enhancers in the model. 
Patterning architectures were considered for enhancers in non-redundant models that were, 
by proportional contribution, ranked second and onwards with at least some proportional 
contribution (>0.2) and low correlation (Pearson's r<0.3) with all other of the nine enhancers 
in the model. Penalized lasso-based regression was used to reduce the number of enhancers 
in the models. The optimal models were selected using 100-fold cross validation and the 
largest value of lambda such that the mean squared error was within one standard error of 
the minimum, using the R package glmnet29,37
SNP analysis
The NIH NHGRI catalog of published genome-wide association studies29 (GWAS catalog, 
downloaded May 7, 2012) contained 7,899 SNP-disease/trait associations. We extended this 
set to 190,356 autosomal associations by propagating disease/trait associations to proxy 
SNPs using the SNAP proxy search tool70 (http://www.broadinstitute.org/mpg/snap/) based 
on linkage disequilibrium (r2 > 0.8) between SNPs (within 250kb) in any of the three 
populations in the 1000 genomes project pilot71 data. The 1000 genome data coordinates 
were in hg18 coordinates and were mapped to hg19 using the UCSC liftOver tool72.
For robust enhancers (center +/− 200 bp), promoters (unique locations of RefSeq protein-
coding gene transcript TSSs +/− 200 bp), exons (unique locations of RefSeq protein-coding 
gene transcript inner exons), and random regions (described above), we calculated the 
number of overlapping and non-overlapping GWAS SNPs associated with each disease/trait 
in the extended GWAS catalog. Non-associated SNPs were extracted from the NCBI single 
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nucleotide polymorphism database (dbSNP, build 135). For each genomic feature and 
disease/trait with an odds ratio > 1, we tested whether the observed overlap was significantly 
greater than expected (Fisher's exact test P < 0.01). Only diseases/traits with more than three 
SNPs overlapping were tested. The same analysis was repeated for each set of significantly 
expressed enhancers associated with each facet. For ease of visualization and interpretation, 
only odds ratios for which the filtering criteria on both significance and overlap number 
were met are shown. Lists of enhancer-overlapped GWAS SNPs are in S16.
Statistical tests, visualization and tools used
Statistical tests were done in the R environment (http://www.R-project.org). Graphs were 
made using lattice, ggplot2 and gplots R packages. Cluster trees were generated by the 
APE73 R package and visualized using the FigTree software (http://tree.bio.ed.ac.uk/
software/figtree/). Intersections of and distances between various genomic features were 
calculated using BEDTools74
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Bidirectional capped RNAs is a signature feature of active enhancers
a, Enhancers identified by co-occurrence of H3K27ac and H3K4me1 ChIP-seq data7, 
centered on P300 binding sites, in HeLa cells were overlaid with HeLa CAGE data (unique 
positions of CAGE tag 5’ ends, smoothed by a 5 bp window), revealing a bidirectional 
transcription pattern. Horizontal axis shows the ± 500 bp region around enhancer midpoints.
b, Density plot illustrating the difference in directionality of transcription according to 
FANTOM5 pooled CAGE tags mapped within ± 300 bp of 22,486 TSSs of RefSeq protein-
coding genes and center positions of 10,138 HeLa enhancers defined as above.
c, Success rates of in vitro enhancer assays in HeLa cells. Vertical axis shows the fraction of 
active enhancers (success defined by Student's t-test, P<0.05 vs. random regions; also see 
Supplementary Figure 9). Numbers of successful assays are shown on the respective bar. See 
main text for details.
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Figure 2. Features distinguishing enhancer TSSs from mRNA TSSs
a, Densities of the genomic and processed RNA lengths of transcripts starting from enhancer 
TSSs and mRNA TSSs using assembled RNA-seq reads from 13 pooled FANTOM5 
libraries.
b, Frequencies of RNA processing motifs (5’ splice motif (5'sS, left panel) and the 
transcription termination site hexamer (TTS, right panel)) around enhancer and mRNA 
TSSs. Vertical axis shows the average number of predicted sites per bp within a certain 
window size from the TSS (horizontal axis) in which the motif search was done. Dashed 
lines indicate expected hit density from random genomic background. The window always 
starts at the gene or enhancer CAGE summits and expands in the sense direction.
c, Average nucleotide frequencies (top panel) and DNase I cleavage patterns (lower panel) of 
enhancer CAGE peaks (arrow at +1 indicates position of the main enhancer CAGE peaks; 
direction of transcription goes left to right) reveal distinct cleavage patterns at sequences 
resembling the INR and TATA elements.
d, De novo motif enrichment analyses around enhancers and non-enhancer FANTOM5 
CAGE-defined TSSs (CAGE TSSs matching annotated TSSs are referred to as 
“promoters”), contingent on CGI overlap. Top enriched/depleted motifs are shown along 
with their best-known motif match name. Enrichment vs. random background is presented as 
a heat map.
e, Vertical axis shows average HeLa CAGE expression fold change vs. control at enhancers 
and RefSeq TSSs after exosome depletion. Horizontal axis shows position relative to the 
TSS or the center of the enhancer. Translucent colors indicate the 95% confidence interval of 
the mean.
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Figure 3. CAGE expression identifies cell type-specific enhancer usage
a, Relationship between CAGE and histone modifications in blood cells. Rows represent 
CAGE-defined enhancers that are ordered based on hierarchical clustering of CAGE 
expression. Columns for the CAGE tags (pink) represent the expression intensity for three 
biological replicates. DNase I hypersensitivity and H3K27ac and H3K4me1 ChIP-seq 
signals ± 1kb around the enhancer midpoints are shown in green, blue and orange, 
respectively.
b, Mean signal of DNase-seq as well as ChiP-seq for H3K27ac and H3K4me1 (vertical axis) 
per cell type (rows) in ± 1kb regions (horizontal axis) around enhancer midpoints, for 
enhancers with blood cell type-specific CAGE expression (columns).
c, Dendrogram resulting from agglomerative hierarchical clustering of tissue samples based 
on their enhancer expression: each leaf of the tree represents one CAGE tissue sample (for a 
labeled tree and the corresponding results on primary cell samples, see Supplementary Figs 
18 and 19). Sub-trees dominated by one tissue/organ type or morphology are highlighted. 
Some of the enhancers responsible for the fetal-specific subgroup in the larger brain subtree 
are validated in vivo (Fig. 4).
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Figure 4. In vivo validation in zebrafish of tissue-specific enhancers
Validations of in vivo activity of CAGE-defined human enhancers CRE1-3 in zebrafish 
embryos at long-pec stage. Each panel shows, from left to right: i) representative YFP and 
brightfield images of embryos injected with the human enhancer gata2 promoter reporter 
gene construct. Muscle (mu) and yolk syncytial layer (ysl) activities are background 
expression coming from the gata2 promoter-containing reporter construct. All images are 
lateral, head to the left. ii) YFP zoom-ins and iii) CAGE expression in TPM in human 
tissues/cell types for the enhancer. Note the correspondence between zebrafish and human 
enhancer usage/expression. Supplementary Figure 20 shows UCSC browser images of each 
selected enhancer.
a, CRE1, ~230kb upstream of the MEFC2 gene, drives highly robust expression in the brain 
(brain) and neural tube (nt). Right panel gives zoom-in overlay image showing expression in 
the forebrain (fb), midbrain (mid), hindbrain (hin) and spinal cord (sp).
b, CRE2, 5kb upstream of the POU3F2 gene, is active in the floor plate (fp). c, CRE3, 10kb 
upstream of the SOX7 gene TSS, shows specific expression in the vasculature (including 
intersegmental vessels (iv), dorsal vein (dv) and dorsal aorta (da)).
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Figure 5. Enhancer usage and specificity in groups of cells
The upper panel gives the number of detected enhancers per million CAGE tags within each 
group (facet) of related cell type libraries. The expression specificity of the enhancers is 
shown as a heat map in the panel below. Colors show the fraction of expressed enhancers in 
each facet (columns) that are in each specificity range (rows). For corresponding plots on 
organ/tissue facets and genes, see Supplementary Figure 21.
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Figure 6. Linking enhancers to TSSs and disease-associated SNPs
a, The proportional contribution (See Methods) of the 10 most proximal enhancers within 
500kb of a TSS in a model explaining gene expression variance (vertical axis) as a function 
of enhancer expression. X axis indicates the position of the enhancer relative to the TSS: 1 
the closest, etc. Bars indicate interquartile ranges and dots medians.
b, Relationship between the number of highly correlated (‘redundant’) enhancers per locus 
(horizontal axis) and the maximal expression (TPM) of the associated TSS in the same 
model over all CAGE libraries (vertical axis).
c, GWAS SNP sets preferentially overrepresented within enhancers, exons and mRNA 
promoters. The horizontal axis gives enrichment odds ratios. The vertical axis shows GWAS 
traits or diseases.
d, Diseases with GWAS associated SNPs over-represented in enhancers of certain 
expression facets. The horizontal axis gives the odds ratio as in panel C, broken up by 
expression facets: each point represents the odds ratio of GWAS SNP enrichment for a 
disease (vertical axis) in a specific expression facet. Summary annotations of point clouds 
are shown. Also see Supplementary Figure 31.
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